{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-004325","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.294413+00:00","generated_at":"2026-06-04T05:20:02.530556+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"KALA BIO reports FY23 net loss $42.2M; Phase 2b PCED trial data expected YE 2024","bullets":["Q4 2023 net loss $8.6M ($3.18/sh) vs $12.8M ($7.97/sh) in Q4 2022.","FY 2023 net loss $42.2M ($17.35/sh) vs $44.8M ($29.48/sh) in FY 2022.","Cash $50.9M at Dec 31, 2023; with $8.6M Mar 2024 placement, runway into Q3 2025.","R&D expenses Q4 $4.7M (up from $3.3M) driven by KPI-012 development costs.","KPI-012 Phase 2b CHASE trial for PCED enrolling; topline data targeted by year-end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-004325","json":"https://secwatch.observer/filing/0001558370-24-004325.json","markdown":"https://secwatch.observer/filing/0001558370-24-004325.md","text":"https://secwatch.observer/filing/0001558370-24-004325.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000155837024004325/0001558370-24-004325-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000155837024004325/kala-20240329x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:20:02.530556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"786117931481751736afc2f0607886ff5c73b3b0","claim":"KALA BIO, Inc. reported financial results for the quarter and year ended December 31, 2023.","evidence_excerpt":"On March 29, 2024, KALA BIO, Inc. announced its financial results for the quarter and year ended December 31, 2023 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837024004325/0001558370-24-004325-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}